Literature DB >> 31553108

Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights.

Lindsey Sawyer1, Heather Creswick1, Raymond Lewandowski1, John Quillin1.   

Abstract

In hereditary cancer, multigene panel testing is currently replacing older single-gene approaches. Patients whose tests were previously uninformative could benefit from updated testing. Research suggests that patients desire to be recontacted about updated genetic testing, but few studies have tested the efficacy of recontact efforts. This study investigated the outcomes of a recontact effort in a hereditary cancer clinic and explored the impact of four different recontact letters, randomized in a 2X2 factorial design. Patients who had negative genetic testing for single genes or conditions were mailed letters inviting them to schedule an appointment to discuss updated testing. Patients were randomized to receive one of four letters and each letter emphasized different implications of updated multigene genetic testing: (a) personal medical management implications, (b) implications for family members, (c) both personal and family implications or (d) a control letter. The proportion of patients who arrived for appointments was assessed approximately 7 months after mailing along with associations with patient demographics and type of letter received. Letters were mailed to 586 patients who had initial testing between 2001 and 2015. Most patients were white (78%) and female (97%) with private insurance (65%). At 7 months, 25 patients (4.3%, 95% CI: 2.6% to 5.9%) had arrived for an appointment. Older age was significantly associated with response rate (p = .01), while type of recontact letter was not (p = .54). This study suggests that recontacting patients about updated genetic testing by mail does not yield a large response. It also suggests that personal and/or familial implications do not seem to be significant factors that determine response rate. Nevertheless, results provide meaningful information for cancer clinics about the outcomes of recontact efforts via informational letter.
© 2019 National Society of Genetic Counselors.

Entities:  

Keywords:  breast cancer; communication; decision making; duty to recontact; ethics; genetic testing; informational letter; multigene panel; recontact; updated genetic testing

Year:  2019        PMID: 31553108     DOI: 10.1002/jgc4.1173

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  3 in total

1.  Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.

Authors:  Shenin A Dettwyler; Erika S Koeppe; Michelle F Jacobs; Elena M Stoffel
Journal:  Fam Cancer       Date:  2021-09-21       Impact factor: 2.446

2.  Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.

Authors:  Ryan Mooney; Whitney Espinel; Ashley Elrick; Kelsey Kehoe; Wendy Kohlmann; Kimberly A Kaphingst
Journal:  J Genet Couns       Date:  2021-09-27       Impact factor: 2.717

3.  Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer.

Authors:  Annie Wang; Jessica N Everett; Jennifer Chun; Cindy Cen; Diane M Simeone; Freya Schnabel
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.